Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267084 | 0.89 | MEN1 (0.54) | MEN1KMT2ATACR3CYP2C9LMNA | |
| SCHEMBL5420651 | 0.87 | DHODH (0.48) | MEN1KMT2ATACR3CYP2C9LMNA | |
| SCHEMBL2372595 | 0.84 | SMN1; SMN2 (0.54) | MEN1KMT2ATACR3LMNAMAPT | |
| SCHEMBL4877723 | 0.83 | CYP2C9 (0.59) | MEN1KMT2ATACR3CYP2C9LMNA | |
| SCHEMBL4875432 | 0.82 | KDM4E (0.49) | MEN1KMT2ATACR3LMNAMAPT | |
| SCHEMBL14564772 | 0.77 | CYP2C9 (0.77) | TACR3CYP2C9 | |
| SCHEMBL2373281 | 0.76 | KDM4E (0.55) | MEN1KMT2ATACR3LMNAMAPT | |
| SCHEMBL4668037 | 0.76 | TACR3 (0.53) | MEN1KMT2ATACR3CYP2C9SMN1; SMN2 | |
| SCHEMBL27729454 | 0.75 | LMNA (0.53) | MEN1KMT2ATACR3LMNAMAPT | |
| SCHEMBL18396429 | 0.75 | MEN1 (0.48) | MEN1KMT2ATACR3CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1809606-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006050991-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | CNR1, ACKR3, HCAR3 | MEN1 2207/4885KMT2A 2462/4885TACR3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.